Evan Tzanis joined Paratek in September 2014 as Vice President of Clinical Development to oversee clinical development strategic and operational deliverables including the design/oversight of clinical trials, biometrics and regulatory affairs. In March 2018, Evan was appointed Chief Development Officer, and in this role he is responsible for overseeing and executing the development strategy for the company. In addition, he is responsible for leading the expansion of the company’s portfolio of products. Mr. Tzanis brings over 20 years of global drug development experience in all aspects of clinical, operational, and regulatory processes. Prior to joining Paratek, Mr. Tzanis served as Head of Clinical Operations and Biometrics at Endo Pharmaceuticals where he also had leadership responsibility in clinical and project management. During his tenure with Endo, Mr. Tzanis was responsible for a number of late stage development programs, including BEMA® Buprenorphine, which successfully completed Phase 3. Prior to joining Endo, Mr. Tzanis was the Global Clinical Program Leader at Wyeth and Pfizer for a number of successful new products on the market today to treat a range of CNS disorders including panic disorder, major depressive disorder, sleep and other medical conditions, including opioid induced constipation and rheumatoid arthritis.